Overview

A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors

Status:
Completed

Trial end date:
2018-09-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ipilimumab is effective in the treatment of select advanced (unresectable, metastatic, or recurrent) solid tumors in Chinese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab